These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 39030788)

  • 1. Costs of diagnosing early Alzheimer's disease in three European memory clinic settings: Results from the precision medicine in Alzheimer's disease project.
    Wimo A; Kirsebom BE; Timón-Reina S; Vromen E; Selnes P; Bon J; Emersic A; Kramberger MG; Speh A; Visser PJ; Winblad B; Fladby T
    Int J Geriatr Psychiatry; 2024 Jul; 39(7):e6126. PubMed ID: 39030788
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The GERAS Study: a prospective observational study of costs and resource use in community dwellers with Alzheimer's disease in three European countries--study design and baseline findings.
    Wimo A; Reed CC; Dodel R; Belger M; Jones RW; Happich M; Argimon JM; Bruno G; Novick D; Vellas B; Haro JM
    J Alzheimers Dis; 2013; 36(2):385-99. PubMed ID: 23629588
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Value of neuropsychological tests, neuroimaging, and biomarkers for diagnosing Alzheimer's disease in younger and older age cohorts.
    Schmand B; Eikelenboom P; van Gool WA;
    J Am Geriatr Soc; 2011 Sep; 59(9):1705-10. PubMed ID: 21883100
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness of the use of biomarkers in cerebrospinal fluid for Alzheimer's disease.
    Valcárcel-Nazco C; Perestelo-Pérez L; Molinuevo JL; Mar J; Castilla I; Serrano-Aguilar P
    J Alzheimers Dis; 2014; 42(3):777-88. PubMed ID: 24916543
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-Effectiveness of Florbetapir-PET in Alzheimer's Disease: A Spanish Societal Perspective.
    Hornberger J; Michalopoulos S; Dai M; Andrade P; Dilla T; Happich M
    J Ment Health Policy Econ; 2015 Jun; 18(2):63-73. PubMed ID: 26231002
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Design and first baseline data of the DZNE multicenter observational study on predementia Alzheimer's disease (DELCODE).
    Jessen F; Spottke A; Boecker H; Brosseron F; Buerger K; Catak C; Fliessbach K; Franke C; Fuentes M; Heneka MT; Janowitz D; Kilimann I; Laske C; Menne F; Nestor P; Peters O; Priller J; Pross V; Ramirez A; Schneider A; Speck O; Spruth EJ; Teipel S; Vukovich R; Westerteicher C; Wiltfang J; Wolfsgruber S; Wagner M; Düzel E
    Alzheimers Res Ther; 2018 Feb; 10(1):15. PubMed ID: 29415768
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prevalence of abnormal Alzheimer's disease biomarkers in patients with subjective cognitive decline: cross-sectional comparison of three European memory clinic samples.
    Wolfsgruber S; Molinuevo JL; Wagner M; Teunissen CE; Rami L; Coll-Padrós N; Bouwman FH; Slot RER; Wesselman LMP; Peters O; Luther K; Buerger K; Priller J; Laske C; Teipel S; Spottke A; Heneka MT; Düzel E; Drzezga A; Wiltfang J; Sikkes SAM; van der Flier WM; Jessen F;
    Alzheimers Res Ther; 2019 Jan; 11(1):8. PubMed ID: 30654834
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Potential Impact of Alzheimer's Disease Early Treatment on Societal Costs of Care in Czechia: A Simulation Approach.
    Broulikova HM; Sladek V; Arltova M; Cerny J
    J Ment Health Policy Econ; 2018 Dec; 21(4):147-161. PubMed ID: 30676992
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 2014 Update of the Alzheimer's Disease Neuroimaging Initiative: A review of papers published since its inception.
    Weiner MW; Veitch DP; Aisen PS; Beckett LA; Cairns NJ; Cedarbaum J; Green RC; Harvey D; Jack CR; Jagust W; Luthman J; Morris JC; Petersen RC; Saykin AJ; Shaw L; Shen L; Schwarz A; Toga AW; Trojanowski JQ;
    Alzheimers Dement; 2015 Jun; 11(6):e1-120. PubMed ID: 26073027
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A comparison of the diagnostic sensitivity of MRI, CBF-SPECT, FDG-PET and cerebrospinal fluid biomarkers for detecting Alzheimer's disease in a memory clinic.
    Morinaga A; Ono K; Ikeda T; Ikeda Y; Shima K; Noguchi-Shinohara M; Samuraki M; Yanase D; Yoshita M; Iwasa K; Mastunari I; Yamada M
    Dement Geriatr Cogn Disord; 2010; 30(4):285-92. PubMed ID: 20861634
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combining Cerebrospinal Fluid Biomarkers and Neuropsychological Assessment: A Simple and Cost-Effective Algorithm to Predict the Progression from Mild Cognitive Impairment to Alzheimer's Disease Dementia.
    Mazzeo S; Santangelo R; Bernasconi MP; Cecchetti G; Fiorino A; Pinto P; Passerini G; Falautano M; Comi G; Magnani G
    J Alzheimers Dis; 2016 Oct; 54(4):1495-1508. PubMed ID: 27589522
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diagnostic and economic evaluation of new biomarkers for Alzheimer's disease: the research protocol of a prospective cohort study.
    Handels RL; Aalten P; Wolfs CA; OldeRikkert M; Scheltens P; Visser PJ; Joore MA; Severens JL; Verhey FR
    BMC Neurol; 2012 Aug; 12():72. PubMed ID: 22883691
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prospective one-year cost-of-illness study in a cohort of patients with dementia of Alzheimer's disease type in Spain: the ECO study.
    Coduras A; Rabasa I; Frank A; Bermejo-Pareja F; López-Pousa S; López-Arrieta JM; Del Llano J; León T; Rejas J
    J Alzheimers Dis; 2010; 19(2):601-15. PubMed ID: 20110605
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Independent information from cerebrospinal fluid amyloid-β and florbetapir imaging in Alzheimer's disease.
    Mattsson N; Insel PS; Donohue M; Landau S; Jagust WJ; Shaw LM; Trojanowski JQ; Zetterberg H; Blennow K; Weiner MW;
    Brain; 2015 Mar; 138(Pt 3):772-83. PubMed ID: 25541191
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness of Alzheimer's disease CSF biomarkers and amyloid-PET in early-onset cognitive impairment diagnosis.
    Contador J; Vargas-Martínez AM; Sánchez-Valle R; Trapero-Bertran M; Lladó A
    Eur Arch Psychiatry Clin Neurosci; 2023 Feb; 273(1):243-252. PubMed ID: 35710952
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Direct costs of Alzheimer's disease in Germany.
    Kiencke P; Daniel D; Grimm C; Rychlik R
    Eur J Health Econ; 2011 Dec; 12(6):533-9. PubMed ID: 20640868
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost of diagnosing dementia in a German memory clinic.
    Michalowsky B; Flessa S; Hertel J; Goetz O; Hoffmann W; Teipel S; Kilimann I
    Alzheimers Res Ther; 2017 Aug; 9(1):65. PubMed ID: 28830516
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness of cerebrospinal biomarkers for the diagnosis of Alzheimer's disease.
    Lee SA; Sposato LA; Hachinski V; Cipriano LE
    Alzheimers Res Ther; 2017 Mar; 9(1):18. PubMed ID: 28302164
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-Utility of Using Alzheimer's Disease Biomarkers in Cerebrospinal Fluid to Predict Progression from Mild Cognitive Impairment to Dementia.
    Handels RLH; Wimo A; Dodel R; Kramberger MG; Visser PJ; Molinuevo JL; Verhey FRJ; Winblad B
    J Alzheimers Dis; 2017; 60(4):1477-1487. PubMed ID: 29081416
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.